Tradewinds LLC. Makes New $988,000 Investment in Amgen Inc. $AMGN

Tradewinds LLC. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,502 shares of the medical research company’s stock, valued at approximately $988,000.

A number of other large investors have also modified their holdings of AMGN. Brighton Jones LLC increased its holdings in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Amgen by 8.4% in the second quarter. Farther Finance Advisors LLC now owns 13,877 shares of the medical research company’s stock valued at $3,875,000 after purchasing an additional 1,076 shares in the last quarter. Abacus FCF Advisors LLC raised its position in Amgen by 226.3% in the 2nd quarter. Abacus FCF Advisors LLC now owns 62,101 shares of the medical research company’s stock worth $17,339,000 after purchasing an additional 43,068 shares during the last quarter. Finally, BTC Capital Management Inc. lifted its holdings in Amgen by 20.5% during the 2nd quarter. BTC Capital Management Inc. now owns 8,039 shares of the medical research company’s stock worth $2,214,000 after buying an additional 1,367 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $330.41 on Monday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock has a market cap of $177.92 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 2.94 and a beta of 0.45. The stock’s fifty day simple moving average is $331.56 and its two-hundred day simple moving average is $306.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the business posted $5.58 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AMGN. Argus upped their target price on shares of Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research report on Tuesday, December 30th. The Goldman Sachs Group upped their target price on Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Royal Bank Of Canada boosted their price objective on shares of Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Piper Sandler lifted their price target on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, Scotiabank started coverage on shares of Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $339.45.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.